A Meta-Analysis of Efficacy and Safety of Infliximab for Prevention of Postoperative Recurrence in Patients with Crohn’s Disease

Figure 6

Forest plot of the safety of Infliximab treatment. (a) Rates of adverse events. (b) Rates of study discontinuation. Red dots represent the RR of rates of adverse events and black dots represent the RR of rates of study discontinuation. Horizontal lines represent 95%Cls of the RR estimates. Diamonds stand for summary effect estimate of the meta-analysis.

(a)

(b)